Jump Financial, LLC Amylyx Pharmaceuticals, Inc. Transaction History

Jump Financial, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$1.65 - $3.24 $29,180 - $57,299	-17,685 Closed	0 $0
Q2 2024 Aug 14, 2024	BUY	$1.62 - $2.71 $28,649 - $47,926	17,685 New	17,685 $33,000
Q4 2023 Oct 21, 2024	SELL	$12.07 - $18.46 $114,628 - $175,314	-9,497 Reduced 41.58%	13,343 $196,000
Q4 2023 Feb 07, 2024	SELL	$12.07 - $18.46 $114,628 - $175,314	-9,497 Reduced 41.58%	13,343 $196,000
Q3 2023 Oct 21, 2024	SELL	$18.08 - $23.45 $2.14 Million - $2.78 Million	-118,607 Reduced 83.85%	22,840 $418,000
Q3 2023 Nov 07, 2023	SELL	$18.08 - $23.45 $2.14 Million - $2.78 Million	-118,607 Reduced 83.85%	22,840 $418,000
Q2 2023 Oct 21, 2024	BUY	$20.98 - $31.42 $2.6 Million - $3.89 Million	123,762 Added 699.81%	141,447 $3.05 Million
Q2 2023 Aug 07, 2023	BUY	$20.98 - $31.42 $2.97 Million - $4.44 Million	141,447 New	141,447 $3.05 Million

127

44.4M

235K

530K

Ticker AMLX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,533,200
Market Cap $310M
Description
Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment...

Get notified when there are updates to the investment portfolio of Jump Financial, LLC, based on Form 13F filings with the SEC.

Stay updated on Jump Financial, LLC with notifications on news.